VEGF/Flk-1 interaction, a requirement for malignant ascites recurrence

被引:28
作者
Stoelcker, B
Echtenacher, B
Weich, HA
Sztajer, H
Hicklin, DJ
Männel, DN
机构
[1] Univ Regensburg, Inst Pathol Tumorimmunol, Dept Pathol, D-93042 Regensburg, Germany
[2] Natl Res Ctr Biotechnol, D-38124 Braunschweig, Germany
[3] Tech Univ Carolo Wilhelmina Braunschweig, D-38124 Braunschweig, Germany
[4] ImClone Syst Inc, Dept Immunol, New York, NY 10014 USA
关键词
D O I
10.1089/10799900050023933
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Vascular endothelial growth factor (VEGF) plays an important role in the production of ascitic fluid associated with malignant tumor growth, In an experimental model for malignant ascites formation, mice were inoculated intraperitoneally with syngeneic mouse sarcoma tumor cells, Ascites development was not prevented by administering tumor necrosis factor (TNF) simultaneously with the tumor cell inoculation. When the malignant ascites was first drained and renewal of ascites was monitored, however, a TNF dose-dependent inhibition of ascitic fluid accumulation was observed. Northern blot analyses indicated transient downregulation by TNF on the expression of VEGF mRNA in tumor cells, Monoclonal antibody, (mAb) DC101 generated against the mouse VEGF receptor Flk-1 prevented the recurrence of malignant ascites in mice similar to TNF inhibition. In addition, exogenous soluble human Flt-1 used as an inhibitor of endogenous VEGF binding also inhibited ascites recurrence, These data demonstrate that the observed inhibitory effect of TNF on reestablishment of malignant ascites can be achieved equally by inhibition of the interaction of VEGF with its receptor Flk-1.
引用
收藏
页码:511 / 517
页数:7
相关论文
共 39 条
[1]   DIFFERENTIAL EXPRESSION OF THE 2 VEGF RECEPTORS FLT AND KDR IN PLACENTA AND VASCULAR ENDOTHELIAL-CELLS [J].
BARLEON, B ;
HAUSER, S ;
SCHOLLMANN, C ;
WEINDEL, K ;
MARME, D ;
YAYON, A ;
WEICH, HA .
JOURNAL OF CELLULAR BIOCHEMISTRY, 1994, 54 (01) :56-66
[2]   Tumor necrosis factor effects on ascites formation in an experimental tumor model [J].
Behammer, W ;
Kluge, M ;
Ruschoff, J ;
Mannel, DN .
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, 1996, 16 (05) :403-408
[3]  
BREIER G, 1992, DEVELOPMENT, V114, P521
[4]   Suppression of glioblastoma angiogenicity and tumorigenicity by inhibition of endogenous expression of vascular endothelial growth factor [J].
Cheng, SY ;
Huang, HJS ;
Nagane, M ;
Ji, XD ;
Wang, DG ;
Shih, CCY ;
Arap, W ;
Huang, CM ;
Cavenee, WK .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (16) :8502-8507
[5]   TUMOR VASCULAR-PERMEABILITY FACTOR STIMULATES ENDOTHELIAL-CELL GROWTH AND ANGIOGENESIS [J].
CONNOLLY, DT ;
HEUVELMAN, DM ;
NELSON, R ;
OLANDER, JV ;
EPPLEY, BL ;
DELFINO, JJ ;
SIEGEL, NR ;
LEIMGRUBER, RM ;
FEDER, J .
JOURNAL OF CLINICAL INVESTIGATION, 1989, 84 (05) :1470-1478
[6]  
CRISCUOLO GR, 1993, YALE J BIOL MED, V66, P277
[7]   The second immunoglobulin-like domain of the VEGF tyrosine kinase receptor Flt-1 determines ligand binding and may initiate a signal transduction cascade [J].
DavisSmyth, T ;
Chen, H ;
Park, J ;
Presta, LG ;
Ferrara, N .
EMBO JOURNAL, 1996, 15 (18) :4919-4927
[8]  
FAJARDO LF, 1992, AM J PATHOL, V140, P539
[9]   VASCULAR-PERMEABILITY FACTOR ENDOTHELIAL GROWTH-FACTOR (VPF/VEGF) - ACCUMULATION AND EXPRESSION IN HUMAN SYNOVIAL-FLUIDS AND RHEUMATOID SYNOVIAL TISSUE [J].
FAVA, RA ;
OLSEN, NJ ;
SPENCERGREEN, G ;
YEO, KT ;
YEO, TK ;
BERSE, B ;
JACKMAN, RW ;
SENGER, DR ;
DVORAK, HF ;
BROWN, LF .
JOURNAL OF EXPERIMENTAL MEDICINE, 1994, 180 (01) :341-346
[10]   TUMOR-NECROSIS-FACTOR TYPE-ALPHA, A POTENT INHIBITOR OF ENDOTHELIAL-CELL GROWTH-INVITRO, IS ANGIOGENIC INVIVO [J].
FRATERSCHRODER, M ;
RISAU, W ;
HALLMANN, R ;
GAUTSCHI, P ;
BOHLEN, P .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1987, 84 (15) :5277-5281